Konruns(SH:603590)2024-04-25 13:56Financial Performance - The company's revenue for Q1 2024 reached ¥199,236,548.72, representing a year-on-year increase of 20.67%[5] - Net profit attributable to shareholders was ¥41,654,332.06, marking a significant increase of 62.28% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥39,656,677.06, reflecting a 74.63% increase year-on-year[5] - Basic and diluted earnings per share were both ¥0.27, an increase of 68.75% year-on-year[5] - Net profit for Q1 2024 was ¥46,845,096.86, representing a 56.83% increase from ¥29,864,395.86 in Q1 2023[22] - Earnings per share for Q1 2024 were ¥0.27, compared to ¥0.16 in Q1 2023, indicating a growth of 68.75%[22] - The total equity attributable to shareholders of the parent company increased to ¥3,144,984,261.72 in Q1 2024 from ¥3,059,941,948.61 in Q1 2023, a growth of 2.77%[18] Cash Flow - The net cash flow from operating activities was ¥45,031,453.62, showing a substantial increase of 202.24% compared to the previous year[5] - In Q1 2024, the net cash flow from operating activities was $45,031,453.62, a significant increase from $14,899,424.58 in Q1 2023, representing a growth of approximately 202.5%[26] - Cash inflow from sales of goods and services was $219,083,077.88 in Q1 2024, an increase of approximately 11.2% from $196,947,841.53 in Q1 2023[26] - Total cash outflow from operating activities decreased to $178,423,292.73 in Q1 2024 from $198,681,014.56 in Q1 2023, a reduction of about 10.2%[26] - The cash paid for purchasing goods and services was $13,950,804.52 in Q1 2024, down from $19,874,395.69 in Q1 2023, indicating a decrease of approximately 29.7%[26] - The cash received from other operating activities was $4,371,668.47 in Q1 2024, a decline from $16,632,597.61 in Q1 2023, representing a decrease of about 73.8%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,891,203,263.76, up 2.92% from the end of the previous year[6] - Total assets as of Q1 2024 amounted to ¥3,891,203,263.76, an increase from ¥3,780,818,095.19 in the previous year[18] - Total liabilities for Q1 2024 were ¥438,590,384.08, up from ¥418,438,293.42 in Q1 2023, marking a rise of 4.52%[18] - Non-current assets totaled ¥2,801,375,598.24 in Q1 2024, compared to ¥2,550,862,348.65 in Q1 2023, reflecting an increase of 9.79%[18] - The total current assets decreased to ¥1,089,827,665.52 from ¥1,229,955,746.54 as of December 31, 2023[16] - The total accounts receivable as of March 31, 2024, is ¥253,287,979.97, slightly down from ¥263,961,417.32 on December 31, 2023[16] Shareholder Information - The total number of common stock shareholders at the end of the reporting period is 11,384[11] - Liu Jianhua holds 50,786,760 shares, representing 31.74% of the total shares, with 9,463,485 shares frozen[11] - The company has not reported any changes in the top 10 shareholders due to securities lending activities[12] Research and Development - The increase in net profit was primarily driven by revenue growth from the "Su Ling" product line and the capitalization of major R&D projects[9] - The clinical trial for Jin Cao Pian has reached its primary research endpoint, with a 12-week treatment period showing significant pain relief[14] - The trial involved 414 participants, with 276 in the treatment group and 138 in the placebo group, achieving a successful pain disappearance rate[14] - The company plans to communicate with regulatory authorities regarding the market application for Jin Cao Pian[14] Other Financial Metrics - The weighted average return on net assets was 1.34%, an increase of 0.48 percentage points compared to the end of the previous year[6] - The company's cash and cash equivalents as of March 31, 2024, amount to ¥314,203,608.71, an increase from ¥230,203,551.41 on December 31, 2023[16] - The company's long-term equity investments as of March 31, 2024, are valued at ¥48,922,261.36, a slight decrease from ¥49,579,276.22 on December 31, 2023[16] - Research and development expenses decreased to ¥11,319,522.81 in Q1 2024 from ¥21,243,679.40 in Q1 2023, a reduction of 46.77%[21] - Other comprehensive income after tax for Q1 2024 was ¥38,109,331.65, down from ¥81,339,307.08 in Q1 2023[22]